Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Neoplasms 2 Smoking 1 Pulmonary Disease, Chronic Obstructive 1 Prostatic Neoplasms 1 Pancreatic Neoplasms 1 Neoplasm Metastasis 1 Myelodysplastic Syndromes 1 Leukemia, Myeloid, Acute 1 Hyperlipoproteinemia Type II 1 Hematologic Neoplasms 1 Hearing Loss 1 Head and Neck Neoplasms 1 Carcinoma, Squamous Cell 1 Advanced Renal Cell Carcinoma (RCC) 1

Interventions

Magnetic Resonance Spectroscopy 49 enzalutamide 46 apalutamide 36 Specimen Handling 34 Androgen Antagonists 30 Abiraterone Acetate 29 Radiosurgery 27 Prednisone 26 darolutamide 25 Docetaxel 23 Pluvicto 22 abiraterone 20 Radiotherapy 19 Biopsy 17 Leuprolide 15 relugolix 11 gallium 68 PSMA-11 11 acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 11 Surveys and Questionnaires 11 Radiation 11 2-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid 11 Standard of Care 10 Nivolumab 10 cabazitaxel 9 X-Rays 9 Triptorelin Pamoate 9 bicalutamide 8 Carboplatin 8 pembrolizumab 7 olaparib 7

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Prostatic Neoplasms × Atorvastatin × 90 days × Clear all

NCT03819101 2026-05-06

PEACE-4

Gustave Roussy, Cancer Campus, Grand Paris

Phase 3 Recruiting

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡